Hematology-Oncology Associates of Northern NJ — Morristown, New Jersey

Hematology-Oncology Associates of Northern NJ is a clinical research site located in Morristown, New Jersey, United States 07960.

Crixeo Clinical Trials Trust Score: 24/100 (FAILING). This profile has not yet been claimed by the site owner.

Hematology-Oncology Associates of Northern NJ has participated in 26 clinical trials.

Therapeutic areas: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Renal Cell Carcinoma.

Sponsors: SCRI Development Innovations, LLC, Astellas Pharma Global Development, Inc., Celgene.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Morristown

Browse all research sites in New Jersey · View every site in Morristown

Sponsor Feasibility Report

Trust Score: 24/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Hematology-Oncology Associates of Northern NJ?

Hematology-Oncology Associates of Northern NJ has a Crixeo Trust Score of 24/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Hematology-Oncology Associates of Northern NJ conducted?

Hematology-Oncology Associates of Northern NJ has 26 clinical trials on record. Their work covers Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Renal Cell Carcinoma.

Is Hematology-Oncology Associates of Northern NJ accredited by Crixeo Clinical Trials?

Hematology-Oncology Associates of Northern NJ has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Hematology-Oncology Associates of Northern NJ?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.